Crx-2

Crx-2 is a **discovery-stage small-molecule anti-infective** being developed by **Cryptyx Biosciences** for **gonorrhea caused by *Neisseria gonorrhoeae***. Based on Cryptyx Biosciences' pipeline materials, the program is described as a natural product-derived small molecule from the company's cryptic biosynthetic gene cluster platform. The disclosed pharmacology is limited, but the company states that Crx-2 acts through a **new target and mode of action** and is **selective against Gram-negative bacteria**. No specific molecular target, formulation, route of administration, or clinical data have been publicly disclosed.